Inducing Selective Starvation of Cancer Cells through Synergistic Inhibition of glycolysis using Mannoheptulose and 2-Deoxy-D-Glucose
DOI:
https://doi.org/10.31351/vol35iss1pp127-141Keywords:
Cancer metabolism, Mannoheptulose, 2-Deoxy-D-Glucose, ATP depletion, Pyruvate accumulationAbstract
The unique opportunity lies in targeting tumor cells through glycolysis, a pathway that compensates for decreased ATP production by increasing sugar consumption. This strategy allows for the development of a novel therapeutic approach, targeting malignant cells with selective pharmacological inhibitors of glycolysis without harming normal cells. In this study, hexokinase, glycolytic enzyme, was targeting to selectively inhibit energy production pathways in cancer cells without harming normal cells. The anticancer mechanisms of 2 Deoxy-D-Glucose (2DG) and Mannoheptulose (MH) in esophagus adenocarcinoma (SK-GT-4) and HBL-100 normal cell lines were investigated using MTT and wound healing assays to assess their cytotoxic effects and cellular proliferation. The apoptosis effect was detected using the AO/EB assay. To confirm the effect of agents on cell energy metabolism, the levels of ATP, pyruvate, and hexokinase were assessed as glycolysis parameters. The results showed significant cytotoxic effects of 2DG and MH on the growth of cancer cells, with a strong synergistic effect when used in combination, especially in SK-GT-4 cells. The IC50 values for 2DG and MH were 278 and 440 µg/mL, respectively, in SK-GT-4 cells, while HBL-100 cells did not reach IC50 values. Wound healing outcomes indicated a decrease in proliferation and invasion of cancer cells. Measurements of ATP and pyruvate levels showed that the combined use of the two drugs more effectively reduces cellular energy compared to using them independently, suggesting a synergistic effect against cancer cells and potential for a more effective treatment approach in the future
How to Cite
Publication Dates
Received
Revised
Accepted
Published Online First
References
L. Siegel, K. D. Miller, N. S. Wagle and A. Jemal. Cancer statistics. CA: a cancer journal for clinicians. 2023; 73: 17-48, https://doi.org/10.3322/caac.21763.
R. Bernards, E. Jaffee, J. A. Joyce, S. W. Lowe, E. R. Mardis, S. J. Morrison and Z. A. Zhang. A roadmap for the next decade in cancer research. Nature Cancer. 2020; 1: 12-17, https://doi.org/10.1038/s43018-019-0015-9.
E. Meacham Corbin and J. Morrison Sean. Tumour heterogeneity and cancer cell plasticity. Nature. 2013; 501: 328-337, https://doi.org/10.1038/nature12624.
S. M. Falih, S. T. Al-Saray, A. A. Alfaris and A. A. Al-Ali. The synergistic effect of eucalyptus oil and retinoic acid on human esophagus cancer cell line SK-GT-4. Egyptian Journal of Medical Human Genetics. 2022; 23: 70, https://doi.org/10.1186/s43042-022-00259-z.
Y. Zhang, Q. Li, Z. Huang, B. Li, E. C. Nice, C. Huang and B. Zou. Targeting glucose metabolism enzymes in cancer treatment: current and emerging strategies. Cancers. 2022; 14: 4568, https://doi.org/10.3390%2Fcancers14194568.
M. H. Sangour, M. I. Ali, Z. W. Atwan and A. A. A. L. A. Al Ali. Effect of Ag nanoparticles on viability of MCF-7 and Vero cell lines and gene expression of apoptotic genes. Egyptian Journal of Medical Human Genetics. 2021; 22: 1-11, https://doi.org/10.1186/s43042-020-00120-1.
M. Trajkovic-Arsic and E. Subramani. Is metabolism the magic bullet for targeted cancer therapy?. BMC cancer. 2023; 23: 1-3, https://doi.org/10.1186/s12885-023-10999-9.
O. Warburg. On the origin of cancer cells. Science. 1956; 123 :309-314, https://doi.org/10.1126/science.123.3191.309.
M. V. Liberti and J. W. Locasale. The Warburg effect: how does it benefit cancer cells?. Trends in biochemical sciences. 2016; 41: 211-218, https://doi.org/10.1016/j.tibs.2015.12.001.
H. Chen, Q. Wu, L. Peng, T. Cao, M. L. Deng, Y. W. Liu and X. F. Yang. Mechanism, Clinical significance, and treatment strategy of Warburg effect in hepatocellular carcinoma. Journal of Nanomaterials. 2021; 2021: 1-10, https://doi.org/10.1155/2021/5164100.
X. B. Li, J. D. Gu and Q. H. Zhou. Aerobic glycolysis in lung cancer. Thoracic Cancer. 2016; 6: 17-24, https://doi.org/10.1111/1759-7714.12148.
F. Cutruzzolà, G. Giardina, M. Marani, A. Macone, A. Paiardini, S. Rinaldo and A. Paone. Glucose metabolism in the progression of prostate cancer. Frontiers in physiology. 2017; 8: 97, https://doi.org/10.3389/fphys.2017.00097.
D. A. Tennant, R. V. Durán and E. Gottlieb. Targeting metabolic transformation for cancer therapy. Nature reviews cancer. 2010; 10: 267-277, https://doi.org/10.1016/j.chembiol.2017.08.028.
D. Hanahan. Hallmarks of cancer: new dimensions. Cancer discovery. 2022; 12: 31-46, https://doi.org/10.1158/2159-8290.cd-21-1059.
Y. He, M. M. Sun, G. G. Zhang, J. Yang, K. S. Chen, W. W. Xu and B. Li. Targeting PI3K/Akt signal transduction for cancer therapy. Signal transduction and targeted therapy. 2021; 6: 425, https://doi.org/10.1038/s41392-021-00828-5.
E. S. Reckzeh, G. Karageorgis, M. Schwalfenberg, J. Ceballos, J. Nowacki, M. C. Stroet and H. Waldmann. Inhibition of glucose transporters and glutaminase synergistically impairs tumor cell growth. Cell chemical biology. 2019; 26: 1214-1228, https://doi.org/10.1016/j.chembiol.2019.06.005.
A. Schoeniger, P. Wolf and F. Edlich. How do hexokinases inhibit receptor-mediated apoptosis?. Biology. 2022; 11: 412, https://doi.org/10.3390/biology11030412.
J. G. Pastorino, N. Shulga and J. B. Hoek. Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. Journal of Biological Chemistry. 2002; 277: 7610-7618, https://doi.org/10.1074/jbc.m109950200.
N. Alzubaidy and H. Sahib. Expression of Vascular Endothelial Growth Factor and Anti-Proliferative Activity of Flaxseed Oil Alone and In Combination with Mefenamic Acid in Cell Lines. Iraqi Journal of Pharmaceutical Sciences. 2024; 33: 46-53, https://doi.org/10.31351/vol33iss1pp46-53.
H. A. M. Rasheed and S. M. Al-Majidi. Synthesis, Molecular Docking Study, Anti-Oxidant and Cytotoxicity Evaluation of New Spiro Six Membered Ring Derivatives of 5-Nitro Isatin. Iraqi Journal of Pharmaceutical Sciences. 2024; 33: 36-48, https://doi.org/10.31351/vol33iss2pp36-48.
M. H. Sangour, I. M. Ali, Z. W. Atwan and A. A. A. L. A. Al Ali. Effect of Ag nanoparticles on viability of MCF-7 and Vero cell lines and gene expression of apoptotic genes. Egyptian Journal of Medical Human Genetics. 2021; 22: 1-11, https://doi.org/10.1186/s43042-020-00120-1.
T. C. Chou. The combination index (CI< 1) as the definition of synergism and of synergy claims. Synergy. 2018; 7: 49-50, https://doi.org/10.1016/j.synres.2018.04.001.
N. Zhou, W. Wang, H. Li, D. Jiang and X. Zhong. Development and investigation of dual potent anticancer drug-loaded nanoparticles for the treatment of lung cancer therapy. Process Biochemistry. 2021; 106: 42-49, https://doi.org/10.1016/j.procbio.2021.03.018.
A. Suarez-Arnedo, F. T. Figueroa, C. Clavijo, P. Arbeláez, J. C. Cruz and C. Muñoz-Camargo. An image J plugin for the high throughput image analysis of in vitro scratch wound healing assays. PloS one. 2020; 15: e0232565, https://doi.org/10.1371/journal.pone.0232565.
E. Bahar and H. Yoon. Modeling and predicting the cell migration properties from scratch wound healing assay on cisplatin-resistant ovarian cancer cell lines using artificial neural network. In Healthcare. 2021; 9: 911, https://doi.org/10.3390/healthcare9070911.
R. J. Tallarida. Quantitative methods for assessing drug synergism. Genes Cancer. 2011; 2: 1003–1008, https://doi.org/10.1177/1947601912440575.
A. G. Al-Ziaydi, A. M. Al-Shammari, M. I. Hamzah, H. S. Kadhim and M. S. Jabir. Hexokinase inhibition using D-Mannoheptulose enhances oncolytic newcastle disease virus-mediated killing of breast cancer cells. Cancer Cell International. 2020; 20: 1-10, https://doi.org/10.1186/s12935-020-01514-2.
J. Li, J. Q. Eu, L. R. Kong, L. Wang, Y. C. Lim, B. C. Goh and A. L. Wong. Targeting metabolism in cancer cells and the tumour microenvironment for cancer therapy. Molecules. 2020; 25: 4831, https://doi.org/10.3390/molecules25204831.
B. Pajak, E. Siwiak, M. Sołtyka, A. Priebe, R. Zieliński, I. Fokt and W. Priebe. 2-Deoxy-d-glucose and its analogs: from diagnostic to therapeutic agents. International journal of molecular sciences. 2019; 21: 234, https://doi.org/10.3390/ijms21010234.
R. Li, S. Mei, Q. Ding, Q. Wang, L. Yu and F. Zi. A pan-cancer analysis of the role of hexokinase II (HK2) in human tumors. Scientific Reports. 2022; 12: 18807, https://doi.org/10.1038/s41598-022-23598-8.
F. Ciscato, L. Ferrone, I. Masgras, C. Laquatra and A. Rasola. Hexokinase 2 in cancer: a prima donna playing multiple characters. International journal of molecular sciences. 2021; 22: 4716, https://doi.org/10.3390/ijms22094716.
M. Ogura, J. Yamaki, M. K. Homma and Y. Homma. Mitochondrial c-Src regulates cell survival through phosphorylation of respiratory chain components. Biochemical Journal. 2012; 447: 281-289, https://doi.org/10.1042/BJ20120509.
V. Gogvadze, S. Orrenius and B. Zhivotovsky. Mitochondria in cancer cells: what is so special about them?. Trends in cell biology. 2008; 18: 165-173, https://doi.org/10.1016/j.tcb.2008.01.006
Y. Huang, F. Ouyang, F. Yang, N. Zhang, W. Zhao, H. Xu and X. Yang. The expression of Hexokinase 2 and its hub genes are correlated with the prognosis in glioma. BMC cancer. 2022; 22: 900, https://doi.org/10.1186/s12885-022-10001-y.
R. Singh, V. Gupta, A. Kumar and K. Singh. 2‐Deoxy‐D‐Glucose: A Novel Pharmacological Agent for Killing Hypoxic Tumor Cells, Oxygen Dependence‐Lowering in Covid‐19, and Other Pharmacological Activities. Advances in pharmacological and pharmaceutical sciences. 2023; 1: 9993386, https://doi.org/10.1155/2023/9993386.
J. Zhao, Y. Ma, Y. Zhang, B. Fu, X. Wu, Q. Li and X. Y. Bai. Low-dose 2-deoxyglucose and metformin synergically inhibit proliferation of human polycystic kidney cells by modulating glucose metabolism. Cell death discovery. 2019; 5: 76, https://doi.org/10.1038/s41420-019-0156-8.
J. M. Brown and W. R. Wilson. Exploiting tumour hypoxia in cancer treatment. Nature reviews. Cancer. 2004; 4: 437–447, https://doi.org/10.1038/nrc1367.
S. Ganapathy-Kanniappan and J. F. H. Geschwind. Tumor glycolysis as a target for cancer therapy: progress and prospects. Molecular cancer. 2013; 12: 1-11, https://doi.org/10.1186/1476-4598-12-152.
J. C. Maher, A. Krishan and T. J. Lampidis. Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer chemotherapy and pharmacology. 2004; 53: 116-122, https://doi.org/10.1007/s00280-003-0724-7.
M. Danos, W. A. Taylor and G. M. Hatch. Mitochondrial monolysocardiolipin acyltransferase is elevated in the surviving population of H9c2 cardiac myoblast cells exposed to 2-deoxyglucose-induced apoptosis. Biochem Cell Biol. 2008; 86: 11-20, https://doi.org/10.1139/o07-156.
Downloads
Published
License
Copyright (c) 2026 Iraqi Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
